Interview with Odnir Finotti, Executive President, Pró Genéricos
When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote…
Address: Rua Alvorada, 1280
CEP : 04550-004
Rua Alvorada, 1280 CEP : 04550-004 São Paulo – SP,Brazil
Tel: (11) 3897-9767
Web: http://www.progenericos.org.br/
Founded in January 2001, the Brazilian Association of Generic Drugs – Pró Genéricos brings together leading laboratories working in the production and marketing generic drugs in the country.
Pró Genéricos is a nonprofit entity whose main mission is to contribute to the improvement of access to medicines in Brazil through the consolidation and expansion of the generics market.
Together, the members of the Pro Generic constitutes around 90% of sales in the generics business in the country. Pro Generic connects various sectors of society, institutions of public and private channels with the actions of its members, giving substance to public debate on issues relevant to the health sector and the development of the pharmaceutical industry in the country .
Since September 2005, Pró Genéricos has been part of the Generic IGPA (International Generic Pharmaceutical Alliance), as an observer. Founded in March 1997, the IGPA is an international organization that seeks to ensure consumer access to medicines that meet quality and economy.
Industry Association.
When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote…
After international tenures in Korea and at Servier’s global headquarters in Paris, Matthieu Mendil has taken the helm of Servier Brazil at a pivotal moment in the affiliate’s evolution. Drawing…
Rogerio Frabetti, General Manager of Biogen Brazil discusses the organisation’s strategic transformation as it expands beyond its neuroscience heritage into immunology whilst maintaining leadership in rare diseases. He articulates Brazil’s…
Rolf Hoenger discusses Roche LATAM’s growth, emphasising patient-centric strategies, untapped access potential, and evidence-based dialogue with policymakers. He highlights accelerated regulatory approvals, digital health initiatives, and Movement Health Foundation projects,…
Roberto Alvarenga, VP at Biotronik’s Latin American operations, reflects on the company’s six decades of innovation and LatAm’s emergence as the firm’s fastest-growing region. He outlines a strategy focused on…
Vaccination remains the most powerful public health intervention ever devised, preventing an estimated 4.4 million deaths each year, according to the WHO. Yet with misinformation spreading faster than science, and…
Adium is one of Latin America’s most expansive pharmaceutical groups, operating across 18 countries with a workforce of 7,000 employees. The organisation has unified its brand identity across the region…
Sylvester Feddes, Country President of Novartis Brazil, outlines the country’s rise as a top global market driven by strong public-private healthcare infrastructure and vast unmet needs. With nearly 100 active…
Sinan Atlig reflects on a 25-year global career spanning Turkey, Colombia, the Middle East, and the US, shaped decisively by vaccine leadership through the COVID-19 era. He identifies vaccines and…
As one of Brazil’s leading pharmaceutical powerhouses, CIMED has redefined what it means to be both national and innovative. Built on a fully verticalised model that spans from R&D to…
Dr Jarbas Barbosa, Director of the Pan American Health Organization (PAHO), discusses the organisation’s evolution from pandemic response to comprehensive health system transformation, regional production capabilities, and the imperative for…
As Latin America’s largest pharma market, worth USD 62 billion in 2024, Brazil is retooling its industry to meet new demands. Driven by changing demographics, chronic disease burdens, and the…
Brazil’s pharmaceutical sector is undergoing a quiet but significant transformation. Once dominated by multinationals and focused largely on generics, a group of leading domestic players is now charting a different…
See our Cookie Privacy Policy Here
